anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed is a method for preparing an extract from Hovenia dulcis thunb. Hovenia dulcis thunb is dried and primarily extracted with water, alcohol and/or acetone. After being filtered, the primary extract is added with 0.001-0.1 wt.& of celite. It is stirred at 50-85 °C for 15-45 min., aged at 5-20 °C for 4-12 hours and further filtered through a filter on which celite is coated. This final extract from Hovenia dulcis thunb is clear and keeps maximal medicinal effects of the tree. Also disclosed are use of such extract from Hovenia dulcis thunb in the food industry and foods containing the extract.
In this group Supervised High intensity Progressive Resistance Training, High intensity weightbearing/Impact exercises and High challenging Balance Training will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
PURPOSE:To obtain an agent having eliminating action on active oxygen, an agent having antiallergic action and a liver function improver, comprising an extract of Struthantus Flexicaulis Mart., a plant known to be effective against hepatopathy, etc., in the South American district from old times, in an organic solvent or water as an active ingredient. CONSTITUTION:A leaf part of Struthantus Flexicaulis Mart living in guava, a kind of mistletoe produced in the South American district, is used in a raw state as it is or dried and ground and then extracted with an organic solvent, water (including hot water) or a mixed solvent of the organic solvent and water and the prepared extract is used as an active ingredient to give an agent having eliminating action on active oxygen, an agent having antiallergic action and a liver function improver. Among the components of the extract, a component having extremely eliminating action on active oxygen is an extract with hot water, especially a water-soluble acidic compound. A component having extremely antiallergic action is a component insoluble in 66% methanol among extract with water and is an extract with hot water. A component having extremely suppressing action on hepatopathy caused by carbon tetrachloride is an extract with hot water. The agent hardly has fear in terms of tachyphylaxis and side effects.
Cataract surgery provides an opportunity to restore the quality of life by improving vision. While monofocal intraocular lenses (IOLs) implantation with monovision has been a common approach for cataract surgery, it may result in limited clarity at the intermediate distance and reduced depth perception. The advent of multifocal IOLs has expanded the possibilities, potentially offering increased visual performance in different ranges of vision. However, the benefits of multifocal IOLs in everyday activities are not fully understood due to the lack of task-based investigations.

To address this gap, a virtual reality-based approach is proposed to simulate daily activities and assess visual performance. This innovative method can provide insights into how multifocal IOLs enhance activities requiring good binocular vision at varying distances, a capability monofocal IOLs may lack. A randomized clinical trial is suggested to compare the TECNIS Synergy multi-focal IOL with the TECNIS monofocal IOL in monovision. Unlike its bifocal predecessors, the TECNIS Synergy IOL is trifocal, providing clear vision at near, intermediate, and far distances. The hypothesis is that patients implanted with the TECNIS Synergy IOL will demonstrate superior visual performance in simulated day and night conditions compared to those implanted with monofocal IOLs and monovision.
<P>PROBLEM TO BE SOLVED: To provide granules having relieved bitterness of pranlukast hydrate, or to provide a preparation containing the granules.  <P>SOLUTION: In providing granules containing pranlukast hydrate and a preparation (tablets quickly disintegrating in the oral cavity) containing the granules, the bitterness can be relieved by reducing the average particle diameter of pranlukast hydrate. Moreover, the effect can be improved by specifying the average particle diameter and the bulk density of the granules containing pranlukast hydrate. Namely, the granules containing pranlukast hydrate and tablets containing the granules show a relieved bitterness and can quickly disintegrate. Therefore, they can be provided as preparations having excellent administration properties. It is also possible to provide a high-content preparation wherein the content of pranlukast hydrate is increased while the content of sugars is decreased.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Amiigo watch during atrial fibrillation cardioversion. Optional sub-study: additional 30 days wearing Amiigo watch as well as BodyGuardian device.
An in vivo optical imaging system and method of identifying unusual vasculature associated with the angiogenic vasculature in tumors. An imaging system acquires images through the breast. Benign, noninvasive oxygen and carbon dioxide are used as vasoactive agents and administered by inhalation to stimulate vascular changes. Images taken before and during inhalation are subtracted. An optical vascular functional imaging system monitors abnormal vasculature through optical measurements on oxy- and deoxy~hemoglobin during inhalation of varying levels of O2 and CO2. The increase in contrast between tumor (cancerous) and normal (noncancerous) tissue is dramatic, facilitating accurate early detection of cancerous tumors and improving sensitivity and specificity (lower false negative and false positive rates). The invention is useful in mammography, dermatology, prostate imaging and other optically accessible areas.
A total of 455 patients were treated for a median time of exposure of 11 months. The incidence of adverse reactions was similar for letrozole and tamoxifen. The most frequently reported adverse reactions were bone pain, hot flushes, back pain, nausea, arthralgia and dyspnea. Discontinuations for adverse reactions other than progression of tumor occurred in 10/455 (2%) of patients on letrozole and in 15/455 (3%) of patients on tamoxifen. 

Adverse reactions, regardless of relationship to study drug, that were reported in at least 5% of the patients treated with letrozole 2.5 mg or tamoxifen 20 mg in the first-line treatment study are shown in Table 3. 

Other less frequent (≤ 2%) adverse reactions considered consequential for both treatment groups, included peripheral thromboembolic events, cardiovascular events and cerebrovascular events. Peripheral thromboembolic events included venous thrombosis, thrombophlebitis, portal vein thrombosis and pulmonary embolism. Cardiovascular events included angina, myocardial infarction, myocardial ischemia and coronary heart disease. Cerebrovascular events included transient ischemic attacks, thrombotic or hemorrhagic strokes and development of hemiparesis.
NEW MATERIAL:A compound of the formula (n is 8, 10 or 12). EXAMPLE:2-deoxy-2-(3-hydroxydodecanamide)-3-O-[3-(3-hydroxytetradecano yloxy) tetradecanoyl]-4-O-phosphono-D-glucopyranose. USE:Having limulus and mitogen activities, inductivity of tumor necrosis factor and interferon, etc., and useful as a medicine, etc. PREPARATION:For example, a glucosamine derivative such as benzyl 2-amino-2- deoxy-4,6-O-isopropylidene-beta-D-glucopyranoside, etc., is used as a starting raw material and acylated by using a hydroxylacyl group and a desired hydroxylacyl group in which an amino group at C-2 position and a OH group at C-3 position are respectively protected. The resultant compound is then subjected to the removal of the isopropylidene group and OH group at C-6 position is protected followed by diphenyl phosphorylation of OH group at C-4 position. Deprotecting is finally carried out by removing phenyl groups from the diphenyl phospholyl group.
The patients will be oriented regarding to the study steps and potential risks of the procedures. They will be assessed by a spasticity-experienced physical therapist. Demographical data will be collected by a questionnaire, the range of movement will be measured with a goniometer, and the muscle tone will be determine by the modified Ashworth scale, with the patient in dorsal decubitus. The presence of hypertonia equal or superior to 2 will assign the respective muscle to injection. Then the patients will be conducted to another room, where another therapist will assess the functional performance by the "timed up and go" (TUG) test, a six-minutes duration walking, and the Fugl-Meyer scale for the upper limb, with the patient in the seated position. During the TUG test the patient is asked to stand up from a chair and walk 3 meters, turn around 180 degrees, and walk back to the chair, assuming 10 seconds as the normal. The 6 minutes walking test will measure the distance in meters in a previously demarcated place. A staff will constantly stimulate the patient verbally, to walk as fast as possible.

Posteriorly the patients will be set in another room, where a neurologist will inject one of the two possible substances, with a pre-determined dosage and dilution. The botulinum toxin group will have the syringe filled with botulinum toxin type A (Dysport) and the control group will have the syringe filled with saline. All the patients will be reassessed in three and six months for a new injection, and will undergo the last evaluation in nine months.

During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training (appendix D). There will be appointments twice a week, one day apart. The duration of the session will be 30 minutes, being 1 minute the interval between the activities. The first 5 minutes will comprise the flexibility exercises, with sustained stretching (15 seconds) and joint mobilizations, followed by a muscle strength exercise involving concentric and eccentric movements, with a progressive charge depending on the patient performance within the following 10 minutes. The last 15 minutes will have a functional training involving gait and upper limb activity combined with endurance training. These activities will be divided into two days: the first day for the trunk and upper limb, and the second for the pelvic, gait, and lower limb exercises. This protocol will be carried out by two physical therapist blinded regarding to the drug injection.
Protein A chromatography is generally less effective in removing antibody aggregates under typical conditions. Provided is a combination and a method that can significantly improve Protein A's aggregate removal capability. The combination comprises polyethylene glycol (PEG) and a salt (chaotropic or kosmotropic) as wash and elution buffer additives. The synergistic effect of salt and PEG results in almost complete separation of monomer from aggregates. For the case used for demonstration, in comparison with the control run the optimized procedure reduces aggregates in elution pool from 20% to 3-4%. This new method, by facilitating aggregate removal at the capture step, improves the overall robustness of downstream process.
Instructed to stand and "briskly" step in place, or "briskly" walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Rather than exercising continuously for at least 10-minute bouts, participants performed multiple (\~9 or 10), short (\~3-5 min) bouts, conveniently incorporated into their daily TV viewing time.
Aerobic exercise participants will receive an exercise prescription based on their heart rate threshold (HRT) for symptom exacerbation during an initial treadmill test. Participants will be asked to exercise once a day up to 90% of their assigned HRT for a minimum of 20 minutes. Participants will wear a heart rate monitor to track their heart rate during aerobic exercise. The treatment will continue until the participant is recovered from his/her concussion, as determined by exercise tolerance and a normal symptom count and clinical examination.
PROBLEM TO BE SOLVED: To obtain a new immune function improver which can increase the immune function in living bodies at the simple composition and is useful in the treatment or the prevention for various infectious diseases including AIDS or immunologic lesion by including active chlorine species. SOLUTION: The immune function improver having preferably isotonic salt concentration is obtained by including active chlorine species (e.g. hypochlorous acid) in the range of 1-1,000 ppm, preferably in addition hydrogen gas. This immune function improver can be administrated in the combination with a reducing relaxation agent, e.g. superoxide dismutase or the like. This immune function improver is preferably obtained by electrolyzing a sterilized salt solution containing a salt content of 0.15-1.0 wt.% at sufficient voltage, ampere and time for giving an electrolyte containing a controlled amount of chlorine species under sterilized atmosphere and, when necessary, adjusting the electrolyte with a sterilized hypertonic salt to the isotonic salt concentration, It is favorable that this immune function improver is adjusted in the pH range of 7.2 to 7.6.
Stress disorders in form of adjustment disorder and burnout syndrom are highly prevalent and cause substantial suffering. Prior evidence suggest that these disorders may be effectively treated with cognitive behavior therapy (CBT), but access to psychological treatment is limited. One possible solution is to provide therapy via the Internet, which has been shown to be effective for anxiety disorders and depression. Internet-based CBT can be described as online bibliotherapy with therapist support via a secure messaging system. In this study psychologists will deliver the treatment. We will investigate the efficacy of Internet-based CBT (ICBT) for adjustment disorder and burnout syndrom in a randomized controlled trial (N=100). Participants will be randomized to active treatment (n=50) or a control condition on waiting list. We expect that participants who receive ICBT will make superior improvements compared to the control condition on measures of stress, burnout, depressive symptoms, general anxiety and general functioning.
<P>PROBLEM TO BE SOLVED: To provide a medical education network system that allows taking courses on medical techniques in the form of classes by utilizing the Internet and mobile terminals.  <P>SOLUTION: The medical education network system comprises training equipment having a training server, an image measuring and diagnostic device, a camera, a microphone and speakers, and installed in a training center; and mobile terminals connected to the training server via a communication means. The training server includes a communication interface connected to the communication means; a digital data input/output part; a course execution control means; a data management control means; and a data storage device. The data storage device has a medical image database, a camera image database, a diagnosis support information database, a patient information database, a question/right answer information database, and a teaching video database, all constructed therein. The course execution control means sends explanations or questions using medical images to the mobile terminals in accordance with the content of a predetermined course selected from the question/right answer information database.  <P>COPYRIGHT: (C)2008,JPO&INPIT
NEW MATERIAL:A compound expressed by formula I (V represents H, halogen or OH; when V represents H, W represents methyl or hydroxymethyl; when W represents methyl, Y represents OH; when X represents hydroxymethyl, Y represents H; when X represents carboxy, Y represents H; when W represents hydroxymethyl, X represents methyl and Y represents OH; when V represents OH, W represents methyl and X represents methyl, formyl, etc.; when X represents methyl Y represents OH; when X represents formyl, etc., Y represents H; when V represents halogen, W represents methyl and X represents methyl, etc.; when X represents methyl, Y represents OH; when V represents H or halogen, Z represents OH, etc., and when V represents OH, Z represents OH, etc.). EXAMPLE:24-Hydroxymilbemycin A4. USE:An insecticide, miticide or vermicide. PREPARATION:A microorganism belonging to the genus Absidia, Circinella or Cunninghamella is cultured in a medium containing a compound expressed by formula II as a substrate.
Previous studies found that the incidence of acute kidney injury afer partial nephrectomy is higher than 30%. In addition to nephron loss induced by renal parenchyma resection, ischemia/reperfusion injury produced by clamping/unclamping of renal arteries is also an important reason. However, studies investigating the effect of circulatory management on the incidence of acute kidney injury after partial nephrectomy are limited.

It has been shown that perioperative hemodynamic optimization protected renal function in surgical patients. And in patients undergoing renal transplantation, adequate hydration and optimal perfusion enhances early graft function. The investigators hypothesize that hydration and circulatory management to guarantee optimal renal perfusion may decrease the occurrence of acute kidney injury after partial nephrectomy. The purpose of this study is to investigate whether circulatory management based on LiDCOrapid hemodynamic monitoring can reduce the incidence of acute kidney injury in patients undergoing partial nephrectomy when compared with routine circulatory management based on blood pressure and urine output monitoring.
<P>PROBLEM TO BE SOLVED: To confirm a past image of a patient during occurrence of abnormality in patient's condition, and to confirm past biological data of the patient during the occurrence of the abnormality in the patient's condition.  <P>SOLUTION: An image processing server 12 receives moving image data from a patient terminal 20 via a LAN 100, and stores the moving image data into an image database 125. A biological information processing server 11 receives biological data from the patient terminal 20 via the LAN 100, and stores the biological data into a biological database 115. A control part 111 determines whether the received biological data are normal or not. When determined that the abnormality occurs in the biological data, the control part 111 transmits abnormality occurrence time and a patient ID to the image processing server 12 via the LAN 100. When receiving the abnormality occurrence time and the patient ID, a control part 121 extracts the corresponding moving image data from the image database 125.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
Acute, localized irritative toxicities of TICE BCG may be accompanied by systemic manifestations, consistent with a "flu-like" syndrome. Systemic adverse effects of 1 to 2 days' duration such as malaise, fever, and chills often reflect hypersensitivity reactions. However, symptoms such as fever of  ≥38.5°C (101.3°F), or acute localized inflammation such as epididymitis, prostatitis, or orchitis persisting longer than 2 to 3 days suggest active infection, and evaluation for serious infectious complication should be considered.

In patients who develop persistent fever or experience an acute febrile illness consistent with BCG infection, 2 or more antimycobacterial agents should be administered while diagnostic evaluation, including cultures, is conducted. BCG treatment should be discontinued. Negative cultures do not necessarily rule out infection. Physicians using this product should be familiar with the literature on prevention, diagnosis, and treatment of BCG-related complications and, when appropriate, should consult an infectious disease specialist or other physician with experience in the diagnosis and treatment of mycobacterial infections.

TICE BCG is sensitive to the most commonly used antituberculous agents (isoniazid, rifampin, and ethambutol). TICE BCG is not sensitive to pyrazinamide.
The present invention provides a dynamic gradient embedding method for purple corn cob anthocyanin. The embedding method takes octenyl succinic anhydride modified acacia, dextrin and hydroxypropyl beta-cyclodextrin as a wall material, and takes macropore resin purified purple corn cob anthocyanin through a water extraction method as a cob material. In order to improve the embedding efficiency, the embedding yield and the storage stability of the anthocyanin, the method provided by the present invention adopts a dynamic gradient embedding method to control wall material concentrations from low to high, thus achieving embedding of the anthocyanin for many times. Through measurement, the embedding efficiency of the purple corn cob anthocyanin microcapsules reaches 94-99%, and the embedding yield of the same reaches 92-96%. Compared to an embedding method with an equal concentration in the whole course, the embedding efficiency is improved by 20-35%, and the embedding yield is improved by 25-40%. After 60-70 hours at room temperature in daylight, the preservation rate of the gradient embedded purple corn cob anthocyanin can reach 90% or above, and the light stable time of the same is shortened by 500-600% compared with equal concentration embedding method in the whole course.
An open treatment 8 week flexible dosing schedule starting with citalopram 10mg/day for the first week, then increasing to 20 mg/day thereafter to treat the depression. At the week 8 visit, citalopram responders will continue citalopram treatment and will be randomized to add-on donepezil or placebo at the week 16 visit.
Therapy with α particle-emitting constructs of the anti-CD33 monoclonal antibody lintuzumab has demonstrated significant tumor effects in AML. Because therapy is selectively targeted to leukemic blasts, it has the potential advantage of less extramedullary toxicity than conventional systemic agents. Moreover, the unique radiobiological features of α particle emissions may permit more efficient tumor cell kill with greater specificity than treatment with β particle-emitting radioisotopes. Objective responses in AML following treatment with 225Ac-lintuzumab have been seen in cytoreduced disease, either following chemotherapy or using a fractionated dosing scheme.

The presence of MRD detectable by cytogenetic techniques and flow cytometric assays indicates a high risk of relapse for AML patients, despite achieving a clinical complete remission. The high linear energy and short range of α emissions make them ideally suited to eradicate MRD, as suggested by the clinical responses observed in earlier studies. To date, 225Ac-lintuzumab has only been studied in patients with overt leukemia. The aim of this phase 1 study is to identify the maximum tolerated dose (MTD) of 225Ac-lintuzumab that can be given safely to AML patients in the postremission setting in order to eliminate detectable MRD and ultimately prolong PFS and OS.
Provided are compositions comprising a cocaine esterase (CocE) and a compound that thermostabilizes the CocE. Also provided are methods of thermostabilizing a cocaine esterase. Additionally provided are methods of treating a mammal undergoing a cocaine-induced condition. Methods of determining whether a compound is a thermostabilizing agent for a protein are also provided. Uses of the above-described compositions for the treatment of a cocaine-induced condition is additionally provided. Additionally provided is an isolated nucleic acid encoding a CocE polypeptide having the substitutions L169K and G173Q, and the CocE polypeptide encoded by that nucleic acid, and pharmaceutical compositions thereof. Further provided is the use of that composition for the manufacture of a medicament for the treatment of a cocaine-induced condition and for the treatment of a cocaine-induced condition.